key: cord-0038168-6mysng0t
authors: Henrickson, Kelly J.
title: Viral pneumonia in children
date: 2006-06-03
journal: Semin Pediatr Infect Dis
DOI: 10.1016/s1045-1870(98)80035-6
sha: 5dffeb429624a9aa9aa5bceba892e37671620220
doc_id: 38168
cord_uid: 6mysng0t

Viral pneumonia causes a heavy burden on our society. In the United States, more than one million cases of pneumonias afflict children under the age of 5 years, costing hundreds of millions of dollars annually. The majority of these infections are caused by a handful of common viruses. Knowledge of the epidemiology of these viruses combined with new rapid diagnostic techniques will provide faster and more, reliable diagnoses in the future. Although the basic clinical epidemiology of these viruses has been carefully investigated over the last 30 years, new molecular techniques are greatly expanding our understanding of these agents and the diseases they cause. Antigenic and genetic variations are being discovered in many viruses previously thought to be homogeneous. The exact roles and the biological significance of these variations are just beginning to be explored, but already evidence of differences in pathogenicity and immunogenicity has been found in many of these substrains. All of this information clearly will impact the development of future vaccines and antiviral drugs. Effective drugs exist for prophylaxis against influenza A and respiratory syncytial virus, and specific therapy exists for influenza A. Ribarivin is approved for use in respiratory synctial virus infections, and it alone or in combination with other agents (eg, IGIV) may be effective in immunocompromised patients, either in preventing the development of pneumonia or in decreasing morbidity and mortality. Many new antiviral agents are being tested and developed, and several are in clinical trials.

isolated during their illnesses, which are frequently complicated by bacterial infections of the lower respiratory tract. 3, [6] [7] In the United States each year, the number of children younger than 5 years of age who have lower respiratory infections (LRI) is estimated at greater than 5 million. 8 The frequency of LRI in children by age and sex from a private practice in Chapel Hill, North Carolina is shown in Figure 1 . Boys have a higher incidence of LRI for the first 10 years of life and one approximately equal to that of girls through adolescence. 9 The incidence of LRI is highest in the first year of life, peaking at between 30 and 35 cases of LRI per 100 children per year, then gradually decreasing to about 5 per 100 children per year in those 9 to 10 years of age, and staying in this range until later in life. l~ Pneumonia represents only one of many clinical presentations for LRI. It represents on average 29 to 38 percent of pediatric inpatient admissions for LRI and is found in 23 percent of children with LRI treated as outpatients. 9,1H4 However, the age-related incidence of pneumonia does not follow exactly the incidence of LRI (Fig 1) . In the first year of life, pneumonia accounts for only approximately 10 percent of the LRI in children observed in an ambulatory care setting. 9 The incidence increases until it reaches a peak in the second and third years of life (approximately 4 to 5 cases/100 child years), then gradually decreases to 2 cases per 100 child years in the 5 to 9 age group and to about 1 case per 100 child years thereafter, 9, [15] [16] In children hospitalized for LRI, pneumonia accounts for approximately 33 to 50 percent of the causes in the first year of life, then declines somewhat until school age, when it increases to become Seminars in Pediatric Infectious Diseases, Vol 9 the major cause for hospitalizations. 15 ,1%18 However, because the majority of LRI in children occurs in their first 5 years of life, as previously stated, pneumonia comprises about one-third of the total LRI observed in the pediatric age range.

Boys develop pneumonia at a slightly higher rate than do girls, but this rate usually is not significant. 9,15,16 In one study, African-American children had significantly more cases of pneumonia than did Caucasians (relative risk = 1.85). 16 Between 3 and 18 percent of admissions to pediatric hospitals in developed nations can be for LRI, depending on the time of year. 12, 16, 19 Approximately 4 percent of all admissions during the fall of 1991 at Children's Hospital of Wisconsin were for pneumonia in children under the age of 6. The actual cost of these respiratory infections has not been calculated, but it is staggering in terms of both dollars and time lost from work for the parents. In the United States, hospitalization costs for infection caused by respiratory syncytial virus (RSV) has been calculated at approximately $300,000,000, 2~ and for emergency room and hospitalization for human paraintluenza viruses 1 and 2 (HPIVs-1 and -2), the costs are approximately $190,000,000.16

The World Health Organization has developed guidelines for defining and managing pneumonia in infants in developing nations. A recent evaluation of these guidelines showed that using cough and/or rapid (difficult) breathing as an initial screen, coupled with a respiratory rate of at least 60 per minute, severe chest wall in-drawing, and nonspecific signs (eg, poor feeding, fever, etc), identified 83 percent of the cases of pneumonia confirmed by chest radiograph. 21

In older infants and children (the majority of pediatric pneumonia cases), the documentation of fever and rales and evidence of pulmonary consolidation on physical examination is the traditional method of diagnosing pneumonia. Most observers also require evidence of radiograph changes sometime during the course of the illness to corroborate the physical examination findings.

Depending on the age of the child and the particular respiratory symptoms,9,11-13 between 50 and 90 percent of LRI are caused by viruses. Viruses have been shown to cause up to 90 percent of pneumonias, especially in the first year of life, 9'15' 2224 and this percentage decreases to approximately 50 percent by school age.9,n Viruses cause a decreasing but still significant number of pneumonia cases in immunocompetent individuals 9 to 10 years of age and older. The percentage of pneumonias with a viral cause eventually declines to approximately 12 percent by adult~ hood. ~,25 This figure does not include excess bacterial pneumonias that occur during specific viral epidemics (eg, yearly influenza or RSV epidemics) or increased pneumonias in the elderly. 26 The viruses that frequently cause LRI in children are listed in Table 1 . Also shown is the relative frequency of each respiratoryvirus as a cause of total viral LRI. The most frequent causes of viral pneumonia in children are listed in Table 2 . The same viruses that cause LRI also are the causes of pneumonia. Several different LRI "syndromes" (eg, bronchiolitis, croup, bronchitis), including pneumonia, can occur at the same time or progressively in the same child. Usually they are caused by a single agent.

Two or more respiratory viruses can be isolated in 5 to 20 In addition, these viruses routinely cause otitis media, pharyngitis, conjunctivitis, and coryza (common cold) in combination with pneumonia. One of the difficulties in trying to summarize incidence data on these viruses is that great differences exist in study designs. Also, these numbers are limited by each institution's ability and interest in recovering certain viruses, whether an outpatient or inpatient population was studied, the number of years or time of year studied, the ages of the children, and whether they reported or looked for other pathogens or causes for each child's lower respiratory symptoms. As an example, in the United States, the sum of the reported incidences of LRI caused byRSV and HPIV-3 during the first year of life is 33 per 100 children per year. 2829 Because this percentage is almost exactly the reported incidence for LRI in general, not much room is left for the other common pathogens. However, a clear pattern among all of the reported data indicates which viruses consistently cause the most infections and illnesses in young children. This pattern has not changed substantially in over 30 years of observation, and it seems to hold true throughout the world. Clearly, in developed nations, RSV is the largest single pathogen resulting in hospitalization. It also seems to be a major cause of pneumonia in developing countries ( Table 2) . RSV is the most common cause of pneumonia in infants and preschool age children. In young hospitalized infants, it routinely causes about 60 percent of pneumonias, a133,3~ Parainfluenza viruses as a group cause at least as many LRI, but they result in lower hospitalization rates and less pneumonia than does RSV. HPIVs-1 and -3 each cause approximately 10 percent of outpatient pneumonias. However, HPIV-3 results in a higher rate of hospitalization for pneumonia in infants and children and is second only to RSV in young infants. HPIVs-2 and -4 both have been reported to cause pneumonia, but the exact proportion of disease caused by these viruses is unclear. Influenza viruses A and B are the next most frequent causes of pneumonia and vary significantly from year to year. Adenoviruses and rhinoviruses are recovered consistently from children with pneumonia. In young infants, enteroviruses play an important role, whereas influenza becomes more important during the school years. RSV; parainfluenza 1, 2, and 3; influenza A and B; and adenovirus together cause the vast majority of all pneumonia in preschool children and are the major causes of viral pneumonia throughout life.3 t A seasonality to the viruses that cause LRI in children has been well-documented and presented (Fig 2) .9'J2'32 Although one virus predominates within a community, overlap always occurs (Fig 3) . Also, considerable variation takes place in the seventy and exact timing of epidemics between years.

RSV, HPIV, influenza, and adenovirus all have been reported to cause serious and fatal LRI in immunocompromised children and adults. Adenoviruses have been associated with pneumonia in an agammaglobulinemic patient ~3 and with bronchial necrosis in a patient with thymic disfunction? 4 Giant-cell pneumonia with HPIV-2 has been reported in severe combined immunodeficiency syndrome (SCIDS) 35 and with HPIV-3 in SCIDS, 36,3y acute myelomonocytic leukemia, 38 and after bone marrow transplantation? 9 Many of these patients had dual infections with other pathogens. Persistent respiratory tract infection and viral excretion by HPIVs-1, -2, and -3 have been described in SCIDS, with HPIV-3 in a child with DiGeorge syndrome after thymic transplant, 4~ and with RSV and HPIV-3 in children infected with HIV. 41,42 The HIV group of children did not seem to have more severe disease with these viruses until they were significantly deficient in T-cells, but the epidemiology of respiratory viruses in this population still needs to be studied. 43 HPIV-3 and influenza have been associated with acute rejection episodes in renal and liver transplant recipients. 44 Influenza has been associated with encephalitis or meningitis in recipients of organ transplant. 44 RSV; HPIVs-1, -2, and -3; and influenzae A and B upper and lower respiratory tract infections, including pneumonia, and death have been reported in organ and bone marrow transplant (BMT) patients. 2,44 Pneumonia occurred in 50 to 78 percent of infected adult immunocompromised patients, and 16 to 44 percent died. The early preengraftment period seems to be a particularly dangerous time to become infected with one of these viruses. In children, the epidemiology and natural history is not well-described. However, 56 percent of 45 children who were recipients of solid organ transplants and were infected with these respiratory viruses developed pneumonia, and 19 percent died. 45 Also, these common respiratory viruses have been shown to cause 20 percent of the episodes of fever in children with cancer. 46 Adenoviruses have been associated with pneumonia in 3 of 83 pediatric BMT patients; two of the three patients died of respiratory failure and one of hepatic failure. 47

The basic structural and biological characteristics for each of the major pediatric respiratory viruses have been well-described in great detail in several recent textbooks. 48,49 R S V RSV is a small pleomorphic enveloped virus with a single strand of ribonucleic acid (RNA) (negative polarity). It belongs to the large paramyxoviridae family of viruses, and thus it can be differentiated morphologically from HPIV, mumps, and measles only by its narrower nucleocapsid. 48 This virus is the number one cause of pediatric hospital admissions for LRI in most areas of the world, 5~ causing almost 100,000 hospitalizations per year in the United States alone) I RSV causes yearly epidemics lasting 3 to 5 months, usually beginning in the early winter or the equivalent rainy season in tropical climates. Most severe disease occurs in children under 1 year of age, with a peak occurring between 2 and 5 months of age, and, as indicated previously, manifests itself as bronchiolitis or pneumonia. Two RSV subtypes (A and B) have been determined mostly by antigenic and genetic differences found in their surface glycoproteins (G and F). 52 Further subgroups of A and B have been described on the basis of antigenic changes on the G protein. 52 Both subtypes circulate in any one year, although often one type predominates. Subtype A strains may be more virulent than are B strains, and they may cause more hospitalization, 53,54 but some investigators have found no difference between subtype strains in type or severity of LRI in children. 55 HPIV Human parainfluenza viruses are separated functionally from RSV by their ability to hemagglutinate red blood cells, a property they share with influenza viruses. Four major virus groups within HP1V (Types 1-4) exist. Further subtypes of HPIV-4 56 and subgroups of HP1V-157-6~ and HPIV-361 have been described.

HP1V-1 usually occurs in biennial epidemics during the fall in both hemispheres. 9,12 At least 50 percent of croup cases (approximately 250,000 per epidemic) in the United States can be linked to this virus. 9 HPIV-1 causes LRI predominantly in children 7 to 36 months of age, with a peak incidence in the second and third years of life. HPIV-I can cause LRI in young infants, but it is rare in children younger than 1 month. In the United States, an estimated 35,000 children younger than 5 years of age are hospitalized each biennium because of HPIV-1. 8'9'14'16'61 Infection with HP1V-2 has been reported to occur biennially with HPIV-1, alternate years with HPIV-1, and more recently in yearly outbreaks. 12,19,62 The majority of respiratory tract infections caused by this virus appear in the fall to early winter. Croup is the most frequent LRI caused by HP1V-2, but all of the respiratory syndromes have been described. LRI caused by this virus have been reported much less frequently than with HPIV-I and -3, perhaps because of difficulties in isolation and detection. The peak incidence of HP1V-2 occurs in the second year of life, but significant numbers of infections occur in infants under 1 year of age, and approximately 60 percent occur in a child's first 5 years. Although frequently overshadowed by HPIVs-1 and -3, HPIV-2 can, in any one year, be the predominant parainfluenza virus causing LRI in young children.

HPIV-3 is unique among the HPIVs in its propensity to infect young infants less than 6 months of age. This virus causes the majority of its infections in the first 12 months of life (approximately 40%), with bronchiolitis and pneumonia being the most common clinical syndromes. It is second only to RSV as a cause of LRI in neonates and young infants. Approximately 20,000 infants and children are hospitalized each year inthe United States because of LRI caused by HP1V-3. Although endemic throughout the world, this virus also occurs in spring epidemics in North America. Epidemics may be dependent on ambient climate conditions. 63 HPIV-4 has been isolated from a very small number of children and adults, and few reports have been published on the epidemiology of this virus. 64"67 Approximately one-third of cases have been in infants less than 1 year of age, one-third in preschool children, and one-third in school-age children and adults. Seroprevalence studies have shown that 60 to 84 percent of infants have significant antibody levels after birth (presumably maternal in origin). These levels drop to 7 to 9 percent by 7 to 12 months of age and stay low before increasing to about 50 percent by 3 to 5 years of age. Antibody levels to HPIV-4 continue to rise throughout childhood until approximately 75 to 95 percent of adults have antibody. 66 All of the different respiratory tract syndromes can be caused by HPIV-4. Severe LRI and pneumonia have been associated with hospitalization of infants and young children. 68 However, based on the seroprevalence data, because infection with HPIV-4 is almost universal, serious disease either is rare or difficult to diagnose.

This important group of orthomyxoviruses can be separated morphologically from its cousins, the paramyxoviruses, by its segmented genome. This characteristic also allows for the genetic reassortment, which leads to rapid shifts in the antigenic characteristics of the influenza viruses and results in pandemic disease. The three major types of influenza (A, B, and C) are differentiated by stable type-specific ribonucleic acid-associated nucleoprotein. Major subtypes infecting humans are determined by variation in the two surface glycoproteins hemagglutinin (H1, H2, and H3) and neuraminidase (N1 and N2). These viruses have many minor antigenic subtypes, with antigenic variations occurring fastest in type A and slowest in type C. Although all three types cause LRI in children, types A and B cause the majority of cases. Influenza epidemics occur each year during the winter, but they vary greatly in their intensity. Also, one type often predominates in anyone year (eg, in 1990-1991, B predominated, and in 1991-1992, A predominated). In years in which influenza type B predominates, increased morbidity in school-age children occurs. 69 Typically, in the early part of the epidemic, influenza infects young school-age children, who then spread it to preschool children and the elderly later in the season. These latter two groups have the highest rates of hospitalization annually (0.5% for infants less than 1 year of age and approximately 0.3% for both children 1 to 4 years and adults over 65 years). 7~ The contribution of influenza to the total cases of viral pneumonia varies year to year and by age, but averages 8 percent. 9,11,12 In preschool age children (1 to 4 years of age), influenza causes all of the typical respiratory syndromes. Very young infants often present with fever only and no specific lower respiratory symptoms. School-age children and adolescents most often present with symptoms of classic influenza with cough, which usually is the only evidence of possible lower respiratory tract involvement. 7~ Influenza may cause a large percentage of the cases of tracheobronchitis in older children?

This small nonenveloped virus is the only deoxyribonucleic acid (DNA) virus to cause frequent LRI in children (Tables 1 and 2) . Its nomenclature has been confusing in the past, with subgrouping by hemagglutination patterns (subgroups 1-4) and by the newer system of determining each strain's guanine plus cytosine content and oncogenic potential in rodents (subgroups AoF). 71"73 Distributed throughout these latter 6 subgroups are 47 distinct serotypes, approximately one-third of which cause most of the disease in humans. 74 In fact, most of the adenoviral LRI in children are caused by subgroups B and C, specifically serotypes 1, 2, 3, 5, and 7. TM Adenoviral infection does not seem to have as much seasonal variation as do those caused by the ortho-and paramyxoviruses. Disease can occur year round and throughout the world, but outbreaks and epidemics occur less often in the fall. 75 The majority of LRI and pneumonia occur in preschool-age children, the most severe disease developing in children younger than 2 years of age. 72 The most common lower respiratory syndrome caused by adenoviruses is pneumonia, but all syndromes can occur. Unique to LRI caused by adenovirus is a pertussis-like syndrome that can mimic clinical pertussis in every way. 76 Asymptomatic rectal excretion (persistence) of this pathogen (as high as 6%) with less then 0.6 percent oral excretion suggests that rectal cultures have no place in the diagnosis of pneumonia caused by this virus. 77,78

These very small (pico) ribonucleic acid (RNA) viruses are probably the most ubiquitous respiratory pathogens on earth (Tables 1, 2, and 3). 79,80 Until recently, rhinoviruses were not thought to cause significant numbers of LRI in children, 9 but several investigators now have shown that these agents can cause up to 12 percent of LRI in young children, 3~ with tracheobronchitis and pneumonia being the most common clinical syndromes. Why previously reported investigations failed to document such high rates of isolation for rhinovirus as a cause of LRI is unclear. However, these viruses are difficult to culture and antigen detection has not been available widely in the past. Many more studies are needed to clarify the roles rhinoviruses play in pediatric LRI and pneumonia. Neutralization assays currently can differentiate approximately 100 rhinovirus serotypes capable of infecting children. 79 These serotypes do not seem to circulate widely between different geographic locations or recur in any predictable pattern. 79 Multiple rhinovirus serotypes may circulate within one community while different serotypes are causing disease nearby. Similarly, the following year, different serotypes may be in both locations. Rhinoviruses can be recovered year round, but they are recovered more often during the spring, summer, and fall. 

This group of viruses is the largest of the RNA viruses found to date, with genomes almost twice as large as those of the paramyxoviridae. 79 Coronaviruses also are extremely difficult to culture, and most studies of LRI or pneumonia in children have not attempted to isolate this agent. The two known human serotypes (HCV-229E and HCV-OC43) 83 do not cross-react with each other. This agent is a frequent cause of URI in children and adults, causing as many as 18 percent in one study, s4 but its role in LRI is still being investigated. Coronoaviruses cause significant numbers of LRI in the large group of children with chronic respiratory disease (asthma, etc), 83,85 but they may play minor roles in other hosts with LRI. 27,86

Person-to-person transmissions of the two most common respiratory virus families (RSV and HPIV) are very similar, but they differ from the other common respiratory viruses in the method. Studies of RSV and HPIV-1 have shown that transmission by small particle aerosols is unlikely. 87,88 Furthermore, studies of RSV have shown that aerosolization of large droplets may be important for transmission to close contacts and surfaces. The secretions on these surfaces allow for contamination of hands, which in turn leads to direct self-inoculation, a9 I-IPIVs-1, -2, and -3 all have been shown to survive up to 10 hours on nonporous surfaces and for 4 hours on porous surfaces. 9~ However, HP1V-3 experimentally placed on fingers has been shown to lose greater than 90 percent of its infectivity in the first 10 minutes and could not be transferred to other fingersfi Therefore, person-toperson spread by direct hand contact seems to be an unlikely means of transmission. Most common disinfectants or antiseptic agents effectively remove RSV or HPIV from surfaces. Alcohol and water were least effective. 9~ Influenza, 92 adenovirus, 93 rhinovirus, 94 and coronavirus 95 all are transmitted by small particle aerosols. These viruses seem to be spread most efficiently without any physical person-to-person contact. Although hands, fomites, and secretions may be able to spread these pathogens, they are not considered the predominant transmission pathway. Influenza and adenovirus show very fast and efficient intrafamily spread, 96,97 whereas rhinovirus and coronavirus have much lower levels of transmission within families. 98,99 Respiratory viruses frequently are transmitted inside medical institutions, including physician offices, hospitals, and chronic care facilities. Nosocomial transmission of RSV and HPIV is most significant in young preschool-age children and the elderly. Transmission to infants varies in direct proportion to the length of hospitalization and has been reported as greater than 45 percent during RSV epidemics. In addition, 50 percent of the staff have become infected. 88 Approximately 20 percent of previously uninfected control children on the same ward with HP1V-3 infected children will excrete virus during their hospital stay. m~ In RSV infections, up to one-third of infants will develop serious LRI. 88,1~ The majority of nosocomial HPIV infections will be asymptomatic, but mild respiratory symptoms will develop in about one-third of patients, and some will experience serious LRI or even death) 9,1~176 Serious sequelae are most common in patients with underlying medical problems. Even in those with only mild symptoms, the mean length of hospitalization usually is increased by many days because of unnecessary tests and therapies that are ordered because of their new signs and symptoms. Less is known about nosocomial transmission of the other common respiratory viruses. Influenza and adenovirus also have caused outbreaks within hospitals and wards during their peak activity within a community. 63,1~176

Isolation of all children admitted to hospitals with respiratory signs and symptoms clearly is not practical. However, enforcing strict hand-washing among patients, cohorting highrisk patients away from those with respiratory infections, and limiting potentially-infected visitors (children and adults) or staff may help decrease nosocomial respiratory infections.

Malnutrition, overcrowding, vitamin A deficiency, lack of breastfeeding, and environmental smoke or toxins, which occur in both developing and developed countries throughout the world, may contribute to morbidity and mortality in pneumonia) ,23,1~

All of the respiratory viruses described above gain access to children via the respiratory epithelia of the eyes, nose, and mouth. The eyes and nose usually are the easiest to infect. Most viral pneumonia in children is thought to develop by direct spread from the upper respiratory tract, with viremia playing no or a very minor role. Adenoviruses may be an exception in this regard. 1~

Local secretory antibody, serum antibody, and cell-mediated immunity all play a role in defending the child from LR1. Nasal secretory IgA may play roles in preventing or ameliorating reinfection with homotypic virus (eg, if challenged with an identical strain) during the same respiratory season, but it does not seem to play a significant role in preventing heterotypic infection or in protecting against spread to the lower respiratory tract once infection takes place. 1~ More work in this area is needed to fully understand the interaction of nasal antibodies with the other parts of the immune system. Serum neutralizing antibody directed at the surface glycoproteins or attachment proteins is very important in protecting the lower respiratory tract.110,112,113 Also, cytotoxic T-cells seem to play a critical role in lower respiratory tract protection. 114~116 Besides the more common alpha-beta T-cells, gamma-delta T-cells and natural killer cells also may be involved. 117,118 Targets for the cytotoxic T-cells have included the surface glycoproteins and internal proteins (eg, nucleoprotein), but which viral epitopes are most important for stimulating this line of defense in children is not known. Antibody-mediated cytotoxic T-cell or complement activity may have some role in viral clearance from the lower respiratory tract, but this remains to be fully elucidated. 119,120

One of the most important aspects of these respiratory pathogens is their ability to escape the immune defenses that were just described. RSV and HPIV can reinfect people multiple times throughout their lives. However, usually only the first encounter with these viruses during infano/and childhood leads to LRI or pneumonia. Most often, repeat infections are manifest as upper respiratory infections until the immune system de-dines with age or becomes deficient. 2,121 RSV and HPIV-3 have higher rates of recurrent pneumonia than do other pathogens. The exact mechanism by which these viruses continue to infect us remains unclear. Maternal antibody, age at exposure, virus, heterologous antibodies, and a child's genetic milieu all influence the development of protection against pneumonia. Pneumonia does not occur after sufficient humoral and cell-mediated immunities are established.

Influenza A has overcome immune mechanisms by rapidly developing antigenic change. Immunity to different serotypes of rhinovirus will develop, but several upper respiratory infections may be needed before immunity is complete. Also, repeat infections with coronaviruses are common and are usually upper respiratory. 122 Very little is known about immune protection against LRI and pneumonia caused by these latter two virus groups, but presumably it is similar to that just discussed for RSV, HPIV, and influenza. Adenovirus is the only DNA virus that is a common respiratory pathogen, and it also is the only pathogen that appears to give long lasting protection. Reinfection with the same s erotype of adenovirus is unusual. 123 Persistent RSV and HPIV infections have been shown in chronically ill or immunosuppressed patients. 124126 Adenovirus rarely may remain latent (no viral replication) for many years 127,128 and perhaps contribute to the development of chronic lung disease later in life. 129

The causative agent in pneumonia cannot be diagnosed reliably by using clinical, radiologic, or nonmicrobiological laboratory tests (eg, C-reactive protein). 13~ Radiograph changes can lag behind the dinical diagnosis, both in showing initial pathology and resolution. In one recent study, only 19 of 39 patients diagnosed clinically with pneumonia had radiographic changes compatible with pneumonia. In the same study, 21 children with acute respiratory disease and radiographic evidence of pneumonia had not received a clinical diagnosis of pneumonia. TM In addition, significant variability (94%) in the radiographic diagnosis of pneumonia has been reported between radiologists and, over time, with the same radiologist) ~2 Indeed, "false" histories have been shown to influence the interpretation of "normal" chest films in children. 133 In the United States, use of serological data for the diagnosis of LRI caused by viruses is not common. However, serological data have been used extensively in other countries as an adjunct to diagnosis by culture and antigen detection. TM Young infants often do not develop a significant serological response to many of these pathogens (eg, RSV). Also, HPIV serotypes, especially HPIVs-1 and 3, often cannot be distinguished. 49 Antibodies to these pathogens can be detected by enzyme immunoassay (EIA), indirect immunofluorescent assay, complement-fixation, hemagglutinin-inhibition, radioimmunoassays, Western blot, and neutralization assays9 Complement-fixation once was the most widely used assay and probably is the most specific for most of these viruses, but EIA has proven to be superior in sensitivity and is becoming more widely used.

A detailed understanding of these agents and their seasonal-ity (Figs 2 and 3) helps suggest the most likely pathogen(s), but as can be seen, most of these viruses are recovered in most months of the respiratory virus "season." Rapid diagnosis of the specific pathogen(s) may be very important for initiating antiviral therapy, cohorting patients, stopping unnecessary antimicrobial therapy (helping to decrease antibiotic resistance), eliminating unnecessary diagnostic tests and procedures, decreasing hospital stay, and reducing costs. 135 One of the most important aspects of diagnosing respiratory viruses in children is the proper collection and transport of samples of respiratory secretions. Throat swabs, nasopharyngeal swabs, nasal wash, and nasal aspiration all have been used successfully to recover these pathogens. The latter two methods have been the most successful. 136-14~ Swabs, brushes, or scrapers have been effective in providing epithelial cells (or antigen) for IFA or EIA. 139,141,142 Nasal-wash specimens should be transported on ice and processed within 8 hours for best virus isolation.

RSV, HPIV, influenza, and adenovirus all can be detected or isolated by many methods. Tissue culture isolation is the standard against which everything else is compared, although rapid antigen detection for RSV without culture confirmation is widely practiced. The first three viral groups can be isolated in 1 to 14 (average, 4 to 5) days in approximately 50 percent of viral pneumonias. 49 Adenovirus usually takes longer to isolate. Tissue culture isolation is affected dramatically by the different methods of obtaining and transporting clinical samples and by cell culture conditions. 143 Many clinical isolates cannot be grown rapidly, even under the best conditions. Furthermore, even after initial identification, additional immunologic assays may need to be performed for specific typing (eg, HPIV-1, influenza A, etc). Accordingly, standard tissue culture rarely is useful in making clinically-relevant decisions.

Enzyme-linked, radio-, and fluroimmunoassays (ie, EIA, RIA, FIA) all have been developed to detect viral antigens from each of these four common pathogens, 144-149 although the majority of data are on RSV and influenza. In general, these assays have good specificity compared with tissue culture (87 to 100%), but they have decreased sensitivities (74 to 85% range). The largest clinical experience is with RSV EIAs, which have been reported to have a sensitivity range of 60 to 90 percent, with the lowest sensitMties being reported from laboratories with the highest yield from tissue culture, 14~ which implies that the sensitivity may actually be only about 60 percent. Antigen detection for adenovirus has yielded the poorest results, with sensitivity as low as 22 percent. 145' 148,15~ Assays for HPIV are not available commercially at this time in the United States. Direct and indirect immunofluorescent assays (DFA/IFA) using monoclonal and polyclonal antibodies have been developed for all of these virus groups (Table  3) . 27 '142'144'145'151-157 In general, the sensitivity of DFAflFA is lower than that ofEIA (--80%), 157 but the specificity usually is slightly higher (average, 91%). Once again, the largest clinical experience is with assays to detect RSV directly from clinical specimens. These studies have shown IFA to be as sensitive if not more sensitive than is EIA. 140,141,144,153"155,158,159 IFA for direct detection of HPIVs-1, -2, and -3 has shown highly variable sensitivities, averaging between 60 and 80 percent and often even much lower. 49 However, with currentlyavailable monoclonal antibodies, improved sensitivities as high as 80 percent are being reported. 157 Specificities usually have been excellent. RSV, HPW, influenza, and adenovirus all have shown 5 to 20 percent false-positive rates for EIA and IFA. 49'144 '153,155'157'159 However, some of these "false" positives may be true positives because the tissue culture was "falsely" negative. In addition, the majority of these studies have suggested that DFA/IFA is subjective and needs significant experience to obtain the best results. Also, in the majority of these studies, 6 to 11 percent of the samples were "uninterpretable" and were removed before statistical analyses were performed.

Centrifugation in tissue culture shell vials coupled with DFAflFA for rapid identification has been shown to speed recovery of most of these viruses, especially adenovirus. 16~ The majority of the data concern RSV and influenza. The published sensitivities compared with tissue culture when read at 48 hours vary between 48 and 100 percent, depending on the virus. Averaging the data indicates that accuracy of adenovirus detection is approximately 70 percent, HPIV (mostly type 3) approximately 80 percent, RSV approximately 90 percent, and influenza approximately 95 percent, compared with detection by standard tissue culture.

The development of rapid molecular techniques such as polymerase chain reaction (PCR) has allowed for the sensitive and specific detection of the majority of these respiratoryviruses from clinical specimens. 161"169 A commercial laboratory has offered multiplex PCR assays for these viruses for several years] 65 A multiplex PCR for HPIVs-1, 2, and 3 was first available in 1995, followed in 1996 by a multiplex PCR to RSVA, B; influenza A, B, and HPIVs-1, -2, and -3. Figure 3 shows the results of this multiplex PCR assay used to diagnose the seven most common respiratory viruses from symptomatic hospitalized children. In 318 children, comparison with standard tissue culture showed a sensitMty of 97 percent (confidence interval 0.89 to 1.0) and a specificity of 98 percent (confidence interval 0.97 to 0.98). This assay takes only about 10 hours to complete, is semiquantitative or quantitative, and is less sensitive to factors that interfere with other methods (eg, viral viability and handling of samples). In addition, PCR technology seems to be more sensitive than is tissue culture or antigen detection, 17~ suggesting that PCR assays for the common respiratory viruses may become the new gold standard in diagnosis. This new method should provide exciting new diagnostic and epidemiological information over the next 5 years.

Rhinoviruses and coronaviruses are difficult to grow in tissue culture, even with experience. 84 Coronavirus isolation may not even be available commercially at this time. 79 Investigators have used standard strains (HCV-229E and OC43) in EIA to detect either virus or antibody to these and closely-related viruses with good success. 27,83,85fl72 Also, IIVA has been used to detect coronaviruses in children. 86 A tissue culture cell line with a cloned human receptor to coronavirus has been developed that may allow increased recovery of these viruses from clinical samples. 173 In addition, PCR-based assays are beginning to be used more frequently in research studies. Application of this technology may provide answers to many important epidemiological and clinical questions.

Many of the viruses that cause pneumonia in children cause other syndromes or have sequelae not related to the respiratory tract (eg, influenza or adenovirus). However, this section will deal only with physical and physiological sequelae of pneumonia in children (and only from developed nations). Certainly, these sequelae are only worse in countries with lower socioeconomic development. The greatest portion of morbidity and mortality caused by these viruses is in young infants and the immunocompromised and medically-compromised populations. The majority of deaths caused by RSV each year occur in infants and children who have congenital heart disease TM or chronic lung disease 175-177 or who are immunocompromisedY 8-~8~ Likewise, HPIV causes death usually only in young infants, the elderly, and the immunocompromised, but it can cause serious morbidity in infants with chronic pulmonary disease. 49,18|

Apnea is a major complication of viral LRI and pneumonia in young infants (younger than 6 months of age). RSV causes the majority of pneumonia in this age group and, therefore, has been implicated most frequently) 82 RSV has not been shown to have a specific pathological role in apnea different from other respiratory viruses that cause similar diseases (eg, HPIV-3, etc). Apnea in infants with RSV infection occurs usually at the beginning of the illness, is nonobstruetive, brief in duration, and, for most infants, does not cause sequelae. 5~ Secondary bacterial infections of the lung can occur with any of these pathogens, especially influenza. 184 Bacterial involvement has been implicated in 31 percent of LRI caused by HP1V) 85 Also, as many as 53 percent of children with bacterial pneumonia have had a concomitant viral infection. 95 Viruses isolated included RSV, HP1V, enterovirus, rhinovirus, and adenovirus. However, the RSV isolation rate has been reported to be the same as the controls without bacterial pneumonia, whereas a statistical association between bacterial pneumonia and viral infection has been noted for HPIV. 95 The exact roles of viral LRI as causative agents in bacterial pneumonia still are being determined.

Long-term pulmonary abnormalities found in children after having RSV pneumonia include decreased gas exchange, 186 restrictive lung disease,187 obstructive lung disease, and hyperreactivity) 86,188 Even adults have been reported to develop chronic lung disease after HPIV LRIj s9 Viral-specific IgE or cytokine production (eg, IL-11, TGF-beta-1, etc) in the lung may play a role in both acute and recurrent wheezing caused by RSV and However, the exact roles of IgE, allergy, cellmediated immunity, and tissue cytokines and the possible biased selection of genetic susceptibilities or "at risk" individuals in long-term follow-up studies remain unclear. Parainfluenza LRI in animal models have shown persistent changes in lung mechanics and hyperresponsiveness, 192 suggesting that viral LRI may lead to real pulmonary damage in some people.

Bronchiolitis obliterans, bronchiectasis, unilateral hyperlucent lung, and chronic atelectasis all have been described after infection by many different viruses. 49 However, adenoviruses have been reported more frequently than have the other common viruses. The exact roles of viruses in general, or adenovirus in particular, in the pathogenesis of these rare sequelae are unknown.

Prophylaxis Antiviral prophylaxis against pneumonia or other LRI needs to be extremely safe, inexpensive, and widely available for longterm use in children. So far, these criteria have been successfully fulfilled only in preventing influenza A infections. The recently approved prophylaxis for severe RSV disease still does not meet these criteria because it is very expensive and in limited supply. lmmunoglobulin (IGIV). Human plasma with high-microneutralization titers to RSV has protected mice from challenge infections with RSV. 193 Also, human immunoglobulin with high-neutralization titers to RSV has decreased viral shedding from challenged primates TM and has been shown to be protective against other paramyxoviruses) 95 Initial studies using standard IGIV to prevent RSV disease in high-risk infants showed only minimal benefit; however, after increasing the specific RSV-neutralizing antibody titer further, trials were successful in showing protection] 96q97 The most recent trial showed a 40 to 60 percent reduction in RSV illness, severity, and hospitalization. 197 In addition, disease caused by other respiratory viruses also was reduced. The American Academy of Pediatrics has recommended the use of RSV-IGIV in children younger than 2 years of age with bronchopulmonary dysplasia currently or recently (last 6 months) on oxygen therapy or who were prematurely born (<32 weeks gestation), but not in children with congenital heart disease, especially cyanotic disease . 198 Amantadine/Rimatidine. These two agents have shown usefulness in chemoprophylaxis against influenza A, showing between 71 and 100 percent protection against illness. Amantadine should be considered during influenza season for any child who is (1) unimmunized and at high risk (Table 4 ), (2) any unimmunized adult/child with regular prolonged contact with high-risk children, (3) immunized high-risk children who were immunized late or with vaccine strains that do not match the current epidemic strains, and (4) as an adjunct in certain Vitamin A. Recent evidence has shown a significant role for vitamin A in reducing morbidity and mortality in acute measles infections, 2~176176 including pneumonia and croupy ~176 Acute infection seems to lower the level of vitamin A in well-nourished children with previously normal levels. 2~ Measles, RSV, and HPIV are closely related paramyxoviruses, but the role of vitamin A in preventing or treating LRI caused by these other viruses is unknown. However, evidence that paramyxovirus specific B and T cell function may be improved with vitamin A supplementation exists, and such could hold true for RSV and HPIV as well. 2~ Nonspecific immunostimulators have been shown to protect against challenge infections with HPIV in animal experiments. 2~176 They have included interferon-gamma, human granulocyte colony-stimulating factor, and human interleukin-1 beta. Many other agents have shown antiviral activity toward these viruses, but none are near clinical application at this time.

benefit when high-titer anti-RSV antibody is administered to animals infected with RSV. 2~ Infants treated with IGIV showed decreased viral shedding and improved clinical response without differences in mortality. 21~ Also, aerosolization of the immunoglobulin recently has been shown effective in dramatically reducing virus titers in infected cotton rats. TM Anecdotal use of immunoglobulin to treat adenovirus disease in immunocomproraised children has been reported with both positive 212 and negative results. 213 Similarly, IGIV has been coupled with ribavirin anecdotally for the treatment of RSV, HPIV, and influenza B pneumonia in immunocompromised patients. 2 Liposome encapsulation as a means of delivery is being investigated for many drugs, including IGIV and antiviral agents. Liposome encapsulated antibody has shown effectiveness both in prophylaxis and in treatment of influenza virus A in mice. 214 Evidence suggests that specific high-titer antiviral IGIV in some form may find a place in the treatment of severe pneumonia in children, However, RSV-IGIV recently has been shown not to be effective in the treatment of high-risk children hospitalized with LRI caused by RSV315

Interferon. Parenteral interferon causes many systemic side effects and, as such, has not been thoroughly investigated as a therapeutic agent in children with pneumonia. 216 Furthermore, adenovirus antagonizes interferon's antiviral activity; accordingly, the use of this drug in the treatment of pneumonia does not seem promising. 217

R~rin. Ribavirin, delivered by small particle aerosol, has been shown to be effective in treating influenza in college students? 1s-22~ Treated students had decreased symptoms and virus excretion. The only published cases of influenza virus LRI treated with ribavirin recovered32 Ribavirin should be consid-ered as an adjunct to amantadine for the treatment of serious LRI with influenza virus. Several clinical trials have shown that the use of ribavirin results in clinical improvement in children with LRI caused by RSV. 222-224 However, more recent efficacy trials have failed to show benefit. At this time, ribavirin should be considered in specific clinical situations when RSV is a likely pathogen. They include young infants (less than 6 weeks of age) and those with severe LR1 or at high risk for serious complications, which have been well-described in the Red Book. 225 High-dose, short-duration therapywith ribavirin has been shown to be safe in intubated and nonintubated infants. ~26 This therapy consists of 6 g/100 mL administered over 2 hours three times each day. Ribavirin has both in vitro and in vivo activity against HPIV. Furthermore, anecdotal reports show decreased HPIV shedding and clinical improvement when infected immunocompromised patients have been treated with ribavirin.

A recent report suggested that ribavirin may be useful in treating RSV, influenza B, and HPW pneumonia in adult BMT patients. 227 Ribavirin should be considered in these types of situations until better drugs become available or controlled trials are completed. Ribavirin has some activity against adenoviruses, rhinoviruses, and coronaviruses in vitro, but it has not been tested clinically. 228

Ganeidovir. Ganciclovir seems to have some inhibitory effect on adenovirus, both in vitro and in vivo, but it has not been studied systematically. 229

Amantadine/Rimantadine. Amantadine has been approved in the United States for over 30 years for the treatment of influenza A. A recent review describes amantadine and rimantadine in great detail33~ Both of these drugs cause a significant improvement in clinical signs and symptoms and decreased viral shedding. Treatment with amantadine currently is recommended for children with severe LRI or those at risk to develop serious LRI when infected with influenza A. This latter group includes immunocompromised children and those with serious medical conditions (Table 4 ). Therapy should be started as soon as possible, preferably within 24 hours.

Although numerous exciting new antiviral agents are being developed, most of them are still years away from being available clinically. However, two agents may be close to being marketed in the United States. The first is zanamivir (GG167), which is a potent and highly specific neuraminidase inhibitor for both influenza A and influenza B. This drug is currently in phase II and HI clinical trials and has shown a decrease of one to two days in the length of time symptoms persist, with no significant toxicity. 231,232 Another agent, MEDI-493 (RSV monoclonal antibody), has just been shown in a phase III clinical trial to reduce RSV hospitalizations by 55 percent. 233 This agent has the advantage that it can be administered intramuscularly and can be used for outpatients.

The only vaccines currently available in the United States are for influenza A, influenza B, and adenovirus. Live oral enteric-coated adenovirus vaccine against types 4 and 7 has been used extensively in the military (greater than 10,000,000 doses). This vaccine is effective in preventing epidemics of acute respiratory disease. Live oral vaccines for strains of adenovirus causing LRI in children (types l, 2, and 5) were tested 20 years ago and found to be effective in stimulating good immunologic responses in seronegative adults, TM but they have not been studied in clinical trials. Problems facing the development of any live adenovirus vaccine for use in children include formulation problems (to maintain protection from the acid environment of the stomach) and the inclusion of the majority of serotypes infecting children. No vaccine is nearing clinical application at this time, but effort is warranted to protect children from LRI caused by this agent, especially among the growing population ofimmunocompromised children.

Influenzae A and B vaccines are widely available, safe, and effective. The current vaccines usually contain two type A strains and one type B, with inactivated whole virus preparations administered to children older than 12 years and "split" vaccine (where the membrane antigens are separated from the core) being administered to younger children. All of the children listed in Table 4 should receive the current vaccine starting at about 6 months of age; the vaccine includes two doses during the first year that vaccine is administered if the child is younger than 9 years of age (see Redbook). Any child over 6 months of age may receive the current influenza vaccine (those with allergies to chickens or eggs should be skin tested first). However, the intramuscular route of vaccination has been an impediment to universal vaccination of young children. Live cold-adapted intranasal influenza vaccines have proven to be safe and immunogenic in infants less than 6 months old and also protective in children and adultsf135 These vaccines currently are being tested for efficacy and could lead to universal infant immunization with the additional benefit of decreased disease in adolescents and adults.

RSV. Currently, the major immunization strategies for RSV involve live cold-adapted (CA) or chemically mutated strains, subunit vaccines, and recombinant vectors. The major protective immunogens on the surface glycoproteins of RSV have been incorporated into vaccinia and adenovirus expression vectorsf136 Studies in cotton rats and some species of primates have shown good immunologic responses and protection from LRI (viral shedding), 2s7,238 whereas results in other species of primates have been less promising. 239 Further evaluation of this approach will have to include the use of suitable vectors for children and efforts to increase immunogenicity. Subunit vaccines containing purified RSV surface proteins have progressed to clinical trials in childrenfl 4~ Vaccines tested in humans and/or animals have contained mostly G, mostly F, and a recombinant chimeric protein F/Gfl 4~ So far, studies have shown poor immunogenicity in seronegative humans or chimpanzees, lowneutralization antibody titers, suppression of immune response in the presence of maternal antibody, and concern over disease potentiation as seen with formalin-inactivated vaccine. These problems render this approach unlikely to produce a safe and efficacious vaccine in the near future.

Live CA strains of RSV A and B currently are being studied and seem to be promising as vaccine candidates. These new vaccine strains differ from previous vaccine strains by containing multiple mutations (3 or more); they have been shown to retain stability against reversion to wild type after replication in rodents and primatesf136,245,246 Human trials are in progress.

HP/V. CA strains of HPIVs-1, -2, and -3 have been developed and are at different levels of testing. Most work has been on HPIV-3, for which clinical trials are in progress. CA HPIV-3 vaccines have shown immunogenicity and attenuation in younger infants, but symptoms still developed. 247 Additional clinical and molecular studies are in progress on CA HPIV-3 strains with greater attenuationf148 AJennerian approach using bovine PW-3 failed to produce significant immune responses in adult volunteers or seropositive childrenY 49 However, initial results in a small number of seronegative infants and children indicate that BPIV-3 is safe, immunogenic, and phenotypically stable. 25~ Further studies are planned using this vaccine. Subunit vaccines containing envelope glycoproteins and virus vectors expressing these same proteins have been immunogenic in animals, 25m56 but clinical trials have not been reported.

ing to a prepaid medical care group over a four-year period. AmJ Epidemio197: [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] 1973 

Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults

Community respiratory viral infections in the immunocompromised host

Epidemiology of acute respiratoryinfections in children of developing countries

Acute respiratory infection in children of developing countries: Challenge of the 1990s

Potential interventions for the prevention of childhood pneumonia in developing countries: A systemic review

Viral etiology and epidemiology of acute respiratory infections in children in

Viral lower respiratory tract infections in Fillipino children

Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice

Jr: Acute lower respiratory infections in nonhospitalized children

The Tucson children's respiratory study. U. Lower respiratory tract illness in the first year of life

Acute respiratory tract infections of children in hospital: A viral and mycoplasma pneumohiae profile

Seasonal pattern in childhood viral lower respiratory tract infections in Melbourne

Contribution of rhinoviruses to respiratory viral infections in childhood. A prospective study in a mainly hospitalized infant population

Impact of viral respiratory diseases on infants and young children in a rural and urban area of southern West Virginia

Pneumonia: An eleven-year study in a pediatric practice

Epidemiology and cost of human parainfluenza virus type one and two infections in young children

Incidence and etiology of pneumonia, croup and bronchiolitis in preschool children belong

Parainfluenza viruses, in Belshe RB

Brief report: parainfluenza virus type 3 infections: Findings in Sydney and some observations on variations in seasonality world-wide

Antigenic characterization of parainfluenza 4A and 4B by the hemagghitination-inbibition test and distribution of HI antibody in human sera

Acute respiratory disease in infancy and childhood: Present understanding and prospects for prevention

The isolation of parainfluenza 4 subtypes A and B in England and serological studies of their prevalence

Recovery and identification of human myxoviruses

Parainfluenza virus type 4 infections in pediatric patients

Management and prevention of influenza and prospects for the future

Adenoviruses in the immunocompromised host

Textbook of Pediatric Infectious Diseases

Adenoviruses, in Fields BN

Molecular epidemiology of adenoviruses associated with acute lower respiratory disease of children in Buenos Aires, Argentina (1984-1988)

Infections in 18,000 infants and children in a controlled study of respiratory tract disease. II. Variation in adenovirus infections by year and season

The role of adenoviruses in the pertussis syndrome

Epidemiology of viral and mycoplasmal agents associated with childhood lower respiratory illness in a civilian population

Adenovirus infections in young children

Textbook of Pediatric Infectious Diseases

The Tecumseh study of respiratory illness. V. Patterns of infection with parainfluenza viruses

Respiratory tract infections due to different rhinovirus serotypes and the influence of maternal antibodies on the clinical expression of the disease in infants

Rhinovirus as a lower respiratory tract pathogen in infants

Epidemiology of coronavirus respiratory infections

Isolation of rhinoviruses and coronaviruses from 38 colds in adults

Recurrent wheezy bronchitis and viral respiratory infections

Diagnosis of human coronavirus infection by immunotluorescence: Method and application to respiratory disease in hospitalized children

Myxovirus dissemination by air

Nosocomial respiratory syncytial virus infections

Modes of transmission of respiratory syncytial virus

Survival and disinfection of parainfluenza viruses on environmental surfaces

Potential role of hands in the spread of respiratory viral infections: Studies with human parainfluenza virus 3 and rhinovirus 14

Human influenza resulting from aerosol inhalation

Aerosol-induced adenoviral illness resembling the naturally occurring illness in military recruits

Aerosol transmission of rhinovirus colds

Pneumonia in pediatric outpatients: Cause and clinical manifestations

Viruses and disease, lB. An outbreak of adenovirus type 7A in a children's home

Original contributions epidemiologic observations of influenza B virus infections in

Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan

Mechanisms of transmission ofrhinovirus infections

Acquisition of paraintluenza 3 virus infection by hospitalized children. I. Frequencies, rates and temporal data

How etiologic, pathologic, and clinical diagnosis can be made in a correlated fashion

Nosocomial influenza infection as a cause of intercurrent fevers in infants

An epidemic of adenovirus 7a infection in a neonatal nursery: Course, morbidity, and management

Outbreak of influenza in a neonatal intensive care unit

Potential interventions for the prevention of childhood pneumonia in developing countries: A systematic review

Leukocyte-associated viremia with adenovirus type 2 in an infant with lower-respiratory tract disease

Secretory immunological response in infants and children to parainfluenza virus types 1 and 2

Parenteral inactivated rhinovirus vaccine: Minimal protective effect

Involvement of gamma delta T cells in respiratory virus infection

Interactions of a nonneutraiizing IgM antibody and complement in parainfhienza virus neutralization

Protection of mice against sendai virus pneumonia by non-neutralizing anti-F monoclonai antibodies

Noninfluenza respiratory infection in long-term care facilities

The behavior of recent isolates of human respiratory coronavirus in vitro and in volunteers: Evidence of heterogeneity among 229E-related strains

Studies ofadenoviruses (APC) in volunteers

Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol

Giant cell pneumonia caused by parainfluenza type 3 in a patient with acute myelomonocytic leukemia

Parainfluenza type 3 in a transplant unit

Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses

Group C adenovirus DNA sequences in human lymphoid cells

Latent viral infections in airway epithelium

Problems in determining the etiology of communityacquired childhood pneumonia

Comparison of the clinical and radiographic diagnosis ofpaediatric pneumonia

Radiological diagnosis of pneumonia in children

Effect of clinicai historyon the interpretation of chest radiographs in childhood bronchiolitis

A hospital-based study of acute viral infections of the respiratory tract in Thai children, with emphasis on laboratory diagnosis

Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients

Parainfluenza viral infections in children: Correlation of shedding with clinical manifestations

Rapid diagnosis of parainfluenza virus infection in children

Rhinovirus infections in an industrial population. IV. Infections within families of employees during two fail peaks of respiratory illness

Comparison of nasal brush and nasopharyngeal aspirate techniques in obtaining specimens for detection of respiratory syncytiai viral antigen by immunoflourescence

Comparison of nasopharyngeai aspirate and nasopharyngeai swab specimens for respiratory syncytiual virus diagnosis by cell culture, indirect immunoflourescence assay, and enzyme-linked immunosorbent assay

Variables affecting the rapid diagnosis of respiratory syncytiai virus (RSV)

Rapid detection of respiratory syncytial virus in nasopharyngeai specimens obtained with the rhinoprobe scraper

Recovery of human parainfluenza virus types one and two

Comparison ofdirectigen RSV with viral isolation and direct immunoflourescence for the identification of respiratory syncytial virus

Comparison of three techniques for detection of respiratory viruses in nasopharyngeal aspirates from children with lower acute respiratory infection

Type-specific detection of parainfluenza viruses by enzyme-immnnoassay and radioimmunoassay in nasopharyngeai specimens of patients with acute respiratory disease

Comparison of monoclonai antibody time-resolved fluoroimmunoassay with monoclonal antibody capture-biotinylated detector enzyme immunoassay for respiratory syncytial virus and parainfluenza virus antigen detection

Enzyme-linked immunosorbent assay (ELISA) for detecting antibodies in sera of patients with adenovirus infection

Evaluation of a rapid enzyme immunoassay for detection of influenza A virus

et ah Rapid diagnosis of parainfluenza virus infection in children

Practical recommendations for the detection of pediatric respiratory syncytial virus infections

Evaluation of the Abbott TESTPACK RSV enzyme immunoassay for detection of respiratory syncytial virus in nasopharyngeal swab specimens

Evaluation ofmonoclonal antibody pool for rapid diagnosis of respiratory viral infections

Efficiency of immunofluorescence for rapid detection of common respiratory viruses

Routine viral culture for pediatric respiratory specimens submitted for direct immunofluorescence testing

Direct detection for viral diagnosis. 13th Annual Clinical Virology Symposium

A rapid test for detection of respiratory syncytial virus in nasopharyngeal secretion

A comparative study of the diagnosis of respiratory virus infections by immunofluorescence and virus isolation in children

Physical and chemical methods for enhancing rapid detection of viruses and other agents

Rapid detection of influenza virus H1 by the polymerase chain reaction

PCR-amplification of influenza A virus specific sequences

Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel

Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: Use of reverse transcription-PCR-enzyme immunoassay

Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-PCRenzyme hybridization assay

Discrimination of respiratory syncytial virus subgroups A and B by reverse transcription-PCR

Detection of respiratory syncytial virus by reverse transcription-PCR and hybridization with DNA enzyme immunoassay

Detection of respiratory syncytial virus by RNA-polymerase chain reaction and differentiation of subgroups with oligonucleotide probes

et ah Type-specific identification of influenza viruses A, B, and C by the polymerase chain reaction

Comparison of reverse transcription-PCR with tissue culture and other rapid diagnostic assays for detection of type A influenza virus

Detection of respiratory syncytial virus, parainfluenza virus 3, adenovirus and rhinovirus sequences in respiratory tract of infants by polyrnerase chain re action and hybridization

Diagnosis of human coronavirus infections in children using enzyme-linked immunosorbent assay

Human aminopeptidase N is a receptor for human coronavirus 229A

et ah Respiratory syncytial viral infection in infants with congenital heart disease

Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis

Respiratory syncytial virus infection in children with bronchopulmonary dysplasia

Clinical characteristics of respiratory syncytial virus infections in healthy versus previously compromised host

Respiratory syncytial viral infection in children with compromised immune function

Cellular response to respiratory varuses with particular reference to children with disorders of cell-mediated immunity

Respiratory syncytial virus infection and the immunocompronfised host

Clinical characteristics of parainfluenza virus infection in hospitalized children

Respiratory syncytial rufus-related apnea in infants. Demographics and outcome

The association ofapnea and respiratory syncytial virus in infants

Influenza A infections in young children

Bacterial involvement in parainfluenza virus infection in children

Long-term prospective study in children after respiratory syncytial virus infection

et ah Respiratory problems two years after acute bronchiolitis in infancy

Lung function and bronchial responsiveness in children who had infantile bronchioliris

Adult brouchiolitis and parainfluenza type 2

Parainfluenza virus-induced persistence of airway inflammation, fibrosis, and dysfunction associated with TGF-beta 1 expression in brown Norway rats

Persistent airway hyperresponsiveness after neonatal viral bronchiolitis in rats

Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

et ah Correlation between the reactivity patterns of monoclonal antibodies to distinct antigenic sites on HN glycoprotein and their protective abilities in Sendai (6/94) virus infection

Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children

Reduction of RSVhospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis

Respiratory syncytial virus immune globulin intravenous: Indications for use

et ah Diminished rhinovirus (RV) illness severity correlates with increased leukocyte ascorbic acid (AA) levels. Abstracts of the 1990 ICAAC

Vitamin C intake and susceptibility to pneumonia

Childhood mortality after a high dose of vitamin a in a high risk population

Vitamin A levels and severity of measles

A randomized, controlled trial of vitamin A in children with severe measles

Micronutrient utilization during measles treated with vitamin A or placebo

Vitamin A levels in children with measles in Long Beach, California

Vitamin A deficiency impairs cytotoxic T lymphocyte activity in Newcastle disease virus-infected chickens

Prophylactic activity against Sendai virus infection and macrophage activation with lipophilic derivatives of N-acetylglucosaminylmuramyl tri-or tetrapeptides

Prophylactic activity of dihydronepatrenoi, a synthetic polyprenol derivative, against Sendai virus infection in mice

Sensitivity of common respiratory viruses to an interferon inducer in human cells

The use of purified immunoglobulin in the therapy of respiratory syncytial virus infection

Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children

Immunotherapy of respiratory syncytial virus infection in cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol

Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody

Dual meningoencephalitis with echovirus type 11 and adenovirus in combined (common variable) immunodeficiency

Prophylaxis and treatment of influenza A virus infection by liposome-mediated passive immunity. Abstracts of the 1992 IC&AC, No. 1557

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSVlower respiratory tract infection in infants and young children at high risk for severe RSV infections

Side effects of long-term treatment with human leukocyte interferon

Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-indued elf-2alpha kinase

Ribavirin small-particle aerosol treatment of influenza

Ribavirin aerosol treatment of influenza

Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H 1N1) and B/Texas//84

Antiviral therapy with small particle aerosols

Aerosolized ribaviron treatment of infants with respiratory syncytial viral infection

RibavMn treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease

Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease

Report of the Committee on Infectious Diseases

High dose-short duration aerosolized ribavirin (Hi) vs. Conventional (Reg) ribavMn (rib) therapy for the treatment of respiratory syncytial virus (RSV) infection in children. Abstracts of the 1992 ICAAC

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections

Ribavirin: A Broad Spectrum Antiviral Agent

Disseminated adenovirus infection after liver transplantation and its possible treatment and gancyclovir (letter)

Antiviral Agents and Viral Diseases of Man

Susceptibility monitoring of influenza virus clinical isolates to the neuraminidase inhibitor zanamivir (GG167) during phase II clinical efficacy trials

Deposition pattern in the respiratory tract of the neuraminidase inhibitor zanamivir, a gamma scintigraphic study. Program and Abstracts of the 37th

Phase l/II, open-label, multi-dose escalation trial of a humanized respiratory virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children

Clinical evaluation of live, oral types 1, 2, and 5 adenovirus vaccines

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: Immunogenicity, and efficacy

Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV)

Evaluation of the protective efficacy of recombinant vaccinia viruses and adenoviruses that express respiratory syncytial virus glycoproteins

Evaluation in nonhuman primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein or respiratory syncytial virus

Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus

Comparative immunogenicity and safety of 2 respiratory syncytial virus (RSV) fusion (F) protein vaccines in 12-30 m children. Abstracts of the 1992 ICAAC

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratol~r syncytial virus induces minimal pulmonary pathology on challenge

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: Comparison of the individual contributions of the F and G glycoprotein to host immunity

A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3 (letter)

KulkamiAB: An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates

Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate

Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 in children

Temperature-sensitive phenotype of the human parainfluenza virus type 3 candidate vaccine strain (cp45) correlates with a defect in the L gene

Evaluation of bovine, cold-adapted human and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity

Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection

Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: Sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities

Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats

Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection

Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine

Occurrence and aetiology of acute respiratory diseases: Results of a long term surveillance programme

Antigen detection in the diagnosis of viral infections

Clinical manifestations of respiratory tract infections due to respiratory syncytial virus and rhinoviruses in hospitalized children